For instance, instead of descriptive results, interventional and controlled studies using leptin or leptin antagonists may help to clarify its role in NAFLD and to evaluate its potential use as a treatment or biomarker of the disease, either at initial steps or at more advanced levels such as NASH with or without fibrosis. This evidence concerns the gene LEP and metabolic dysfunction-associated steatotic liver disease.